Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845222 | 0.90 | REN (0.41) | ALDH1A1POLBTP53RAB9A | |
| SCHEMBL24174311 | 0.78 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| Bromide SCHEMBL22717326 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL22845210 | 0.74 | ALDH1A1 (0.42) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL22845203 | 0.74 | KDM5A (0.42) | ALDH1A1MAPTMEN1KMT2AHSP90AA1 | |
| SCHEMBL24469915 | 0.72 | ROCK2 (0.33) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL22845485 | 0.71 | ALDH1A1 (0.41) | ALDH1A1LMNATSHRHTT | |
| SCHEMBL22845404 | 0.70 | ALDH1A1 (0.47) | ALDH1A1TSHRSMN1; SMN2MAPTMEN1 | |
| SCHEMBL24469784 | 0.69 | CDK2 (0.37) | ALDH1A1LMNAMAPTTP53 | |
| SCHEMBL24469968 | 0.68 | KDM4C (0.44) | ALDH1A1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | ALDH1A1 648/4885G6PD 1509/4885CYP3A4 68/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | ALDH1A1 648/4885G6PD 1509/4885CYP3A4 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.